Tempus AI, Inc. (NASDAQ:TEM) COO Sells $792,200.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 20,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00. Following the completion of the transaction, the chief operating officer now owns 982,442 shares in the company, valued at $38,914,527.62. This represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ryan Fukushima also recently made the following trade(s):

• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The stock was sold at an average price of $40.23, for a total transaction of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The shares were sold at an average price of $42.51, for a total transaction of $5,101,200.00.

Tempus AI Trading Up 0.1 %

NASDAQ TEM opened at $37.52 on Friday. The company has a fifty day simple moving average of $48.45 and a two-hundred day simple moving average of $46.89. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI in the third quarter worth $30,000. Geode Capital Management LLC raised its holdings in shares of Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after buying an additional 539 shares during the last quarter. Vestor Capital LLC purchased a new position in shares of Tempus AI in the third quarter worth $153,000. The Manufacturers Life Insurance Company raised its holdings in shares of Tempus AI by 10.2% in the third quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after buying an additional 2,765 shares during the last quarter. Finally, Stifel Financial Corp purchased a new position in shares of Tempus AI during the third quarter worth $218,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Piper Sandler reiterated a “neutral” rating and set a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Guggenheim assumed coverage on shares of Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 price objective on the stock. Bank of America increased their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Finally, Loop Capital increased their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and an average price target of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.